MedPath

Tagged News

Tata Memorial Centre Partners with GE HealthCare to Establish Advanced Cancer Research & Innovation Centre

AIOncology
  • Tata Memorial Centre has signed a Memorandum of Understanding with GE HealthCare Technologies Inc. to establish a Cancer Research & Innovation Centre, with TMC serving as the clinical oncology partner and GE HealthCare as the technology partner.
  • The five-year collaboration will focus on accelerating development and validation of AI-based applications for medical imaging, clinical workflows, and advanced visualization tools in oncology care.
  • The partnership addresses the urgent need for enhanced cancer care as India faces a forecasted 12.8% rise in cancer incidence by 2025, with emphasis on early detection and equitable access challenges.
  • A Joint Working Group will chart key project areas including data annotation for application development and enterprise health informatics solutions to support personalized cancer care.

Phase 3 Trial Shows Promise for Adjuvant BRAF/MEK Inhibitor Combination in High-Risk Melanoma

Targeted TherapyOncology
  • The phase 3 EORTC-2139-MG/Columbus-AD trial demonstrated that adjuvant encorafenib plus binimetinib improved 12-month recurrence-free survival to 86% versus 70% with placebo in patients with stage IIB/C BRAF V600-mutant melanoma.
  • The combination therapy was generally well tolerated with a manageable safety profile, though 33% of patients discontinued treatment due to adverse events.
  • This represents the first randomized adjuvant trial of BRAF-directed therapy in stage IIB/IIC melanoma, potentially offering patients an alternative to immunotherapy in the adjuvant setting.

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Active, Not RecruitingPhase 3
Pierre Fabre Medicament
Posted 5/2/2022

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453CompletedPhase 3
Pfizer
Posted 9/12/2013

Zydus Lifesciences Secures Exclusive Rights to Agenus' BOT/BAL Cancer Immunotherapy for India and Sri Lanka

Monoclonal AntibodyOncology
  • Zydus Lifesciences has signed an exclusive licensing agreement with US-based Agenus Inc to commercialize the investigational cancer therapy combination of Botensilimab (BOT) and Balstilimab (BAL) in India and Sri Lanka.
  • The BOT/BAL combination therapy is currently in advanced clinical trials and has demonstrated significant clinical activity across nine cancer types in over 1,200 patients, including late-stage and neoadjuvant settings.
  • Under the agreement, Zydus will pay Agenus a 5% royalty on net sales following regulatory approval and will take responsibility for clinical development and regulatory approvals in the specified territories.
  • Zynext Ventures, the venture capital arm of Zydus, has also made a strategic investment in Agenus to accelerate development of the BOT/BAL programme and expand into high-unmet need indications.

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

NCT06251973RecruitingPhase 2
Memorial Sloan Kettering Cancer Center
Posted 2/1/2024

Rigosertib Achieves 80% Response Rate in First Clinical Trial for Rare RDEB-Associated Skin Cancer

Rare DiseaseOncologyOrphan Drug
  • Rigosertib demonstrated an 80% overall response rate with 50% complete responses in the first-ever clinical trial for RDEB-associated squamous cell carcinoma, published in the British Journal of Dermatology.
  • The trial addressed a critical unmet medical need in recessive dystrophic epidermolysis bullosa patients who develop aggressive skin cancers with cumulative death risks of 70% and 78.7% by ages 45 and 55, respectively.
  • Traws Pharma is actively seeking development and commercialization partners for rigosertib, a small molecule PLK-1 kinase inhibitor, as no approved therapies currently exist for this devastating condition.

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

NCT04177498CompletedEarly Phase 1
Thomas Jefferson University
Posted 8/24/2021

Rigosertib for RDEB-SCC

NCT03786237RecruitingPhase 1
Prof. Johann Bauer
Posted 4/12/2021

Spago Nanomedical's Radioligand Therapy 177Lu-SN201 Advances in Phase I/IIa Trial Following Positive Safety Review

Oncology
  • Spago Nanomedical's Data Monitoring Committee recommended continuing the Tumorad-01 phase I/IIa study with radioligand therapy 177Lu-SN201 after analyzing safety data from 10 patients across three dose cohorts.
  • The study has demonstrated acceptable safety profiles across three dose levels (5, 10, and 15 MBq/kg) in patients with eight different tumor types, with side effects mainly limited to transient platelet impacts.
  • The company plans to recruit two additional patients at the highest dose level of 15 MBq/kg while continuing treatment at lower doses, targeting completion of the phase I portion in 2025.
  • This first-in-human study evaluates safety, tolerability, dosimetry, and initial efficacy of the candidate drug, with the phase I portion designed to identify optimal therapeutic dosing for subsequent efficacy-focused phases.

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

NCT06184035RecruitingPhase 1
Spago Nanomedical AB
Posted 11/30/2023

Terbium-161 Radioimmunotherapy Shows Superior Efficacy Against Lymphoma in Preclinical Studies

Targeted TherapyMonoclonal AntibodyOncology
  • Researchers at the Paul Scherrer Institute have developed a novel radioimmunotherapy using terbium-161 attached to CD30-targeting antibodies for lymphoma treatment.
  • The terbium-161 therapy demonstrated 2 to 43 times greater cancer cell killing efficacy compared to lutetium-177 in laboratory studies.
  • Preclinical mouse studies showed treated animals survived twice as long as controls, with some achieving complete cancer remission.
  • The therapy targets CD30 receptors present in approximately one-third of lymphoma patients and could address previously difficult-to-treat T-cell lymphomas.

Amivantamab Shows Promise in Colorectal Cancer as Phase 3 Trials Launch Following Encouraging Phase 1b/2 Results

Oncology
  • The phase 1b/2 OrigAMI-1 trial demonstrated that amivantamab monotherapy achieved a 22% objective response rate and 3.7-month median progression-free survival in advanced colorectal cancer patients.
  • Combination therapy with amivantamab plus FOLFOX or FOLFIRI showed enhanced efficacy with a 43% objective response rate and 7.4-month median progression-free survival in a smaller patient cohort.
  • Two phase 3 trials, OrigAMI-2 and OrigAMI-3, have been launched to further evaluate amivantamab versus cetuximab in metastatic colorectal cancer patients with RAS and BRAF wild-type status.
  • The bispecific antibody's trifunctional mechanism targeting EGFR and MET receptors, plus immune cell-directed activity, positions it as a potential improvement over current anti-EGFR therapies for the 50% of metastatic colorectal cancer patients eligible for treatment.

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595RecruitingPhase 1
Janssen Research & Development, LLC
Posted 7/29/2022

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786RecruitingPhase 3
Janssen Research & Development, LLC
Posted 10/18/2024

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094RecruitingPhase 3
Janssen Research & Development, LLC
Posted 12/12/2024

Enterome Reports Positive Phase 2 Data for EO2463 in Indolent Non-Hodgkin Lymphoma

Oncology
  • Enterome will present positive Phase 2 data for EO2463, its lead OncoMimics immunotherapy, in treating indolent non-Hodgkin lymphoma at the International Conference on Malignant Lymphoma on June 21, 2025.
  • The SIDNEY study demonstrates EO2463's potential as a frontline therapy across multiple patient groups, including watch-and-wait, first-line, and relapsed/refractory settings.
  • Enterome recently held a positive Type-C meeting with the FDA, establishing a clear regulatory pathway to marketing approval for EO2463 in indolent non-Hodgkin lymphoma.
  • EO2463 is an innovative off-the-shelf immunotherapy combining four synthetic peptides that target multiple B-cell markers including CD20, CD22, CD37, and CD268.

Kivu Bioscience Partners with Sterling Pharma for Phase 1 Manufacturing of Next-Generation ADC KIVU-107

Oncology
  • Kivu Bioscience has selected Sterling Pharma Solutions to manufacture cGMP clinical material for its lead oncology ADC candidate KIVU-107 ahead of Phase 1 trials.
  • KIVU-107 is described as a potential first-in-class antibody-drug conjugate featuring site-specific conjugation technology that positions the linker-payload in a natural antibody cavity.
  • The partnership leverages Sterling's dedicated bioconjugation facility in Deeside, UK, which recently received a £10 million investment to double its GMP manufacturing capacity.
  • The collaboration includes comprehensive development activities from process familiarization through analytical development and scale-up preparation for clinical manufacturing.

Sutro Biopharma Appoints Greg Chow as CFO to Advance ADC Pipeline

Oncology
  • Sutro Biopharma appointed Greg Chow as Chief Financial Officer effective June 2, 2025, bringing over 25 years of executive leadership experience in biotech finance and operations.
  • Chow previously served as CFO at multiple biotech companies including Freenome Holdings and Frontier Medicines, where he guided major financing rounds and strategic collaborations.
  • The appointment aims to strengthen Sutro's financial position as the company advances its pipeline of novel exatecan-based and dual-payload antibody drug conjugates through clinical milestones.
  • Sutro granted Chow equity compensation including 100,000 restricted stock units and options for 275,000 shares under the company's 2021 Equity Inducement Plan.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.